Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Julphar
Teva
Healthtrust
McKinsey
Citi
Chinese Patent Office
Deloitte
Daiichi Sankyo
Colorcon

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,101,866

« Back to Dashboard

Summary for Patent: 7,101,866
Title:Anti-inflammatory androstane derivative
Abstract:According to one aspect of the invention, there is provided a compound of formula (I) ##STR00001## and solvates thereof. There are also provided compositions containing the compound, processes for preparing it, and its use in therapy.
Inventor(s): Biggadike; Keith (Stevenage, GB), Coote; Steven John (Stevenage, GB), Nice; Rosalyn Kay (Stevenage, GB)
Assignee: Glaxo Group Limited (Greenford, GB)
Application Number:09/958,050
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Delivery; Use; Process; Dosage form;

Drugs Protected by US Patent 7,101,866

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Glaxosmithkline ARNUITY ELLIPTA fluticasone furoate POWDER;INHALATION 205625-001 Aug 20, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER ➤ Subscribe
Glaxosmithkline ARNUITY ELLIPTA fluticasone furoate POWDER;INHALATION 205625-002 Aug 20, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER ➤ Subscribe
Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275-001 May 10, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS ➤ Subscribe
Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275-001 May 10, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER ➤ Subscribe
Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275-002 Apr 30, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER ➤ Subscribe
Glaxosmithkline TRELEGY ELLIPTA fluticasone furoate; umeclidinium bromide; vilanterol trifenatate POWDER;INHALATION 209482-001 Sep 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Glaxosmithkline Cons FLONASE SENSIMIST ALLERGY RELIEF fluticasone furoate SPRAY, METERED;NASAL 022051-002 Aug 2, 2016 OTC Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,101,866

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0019172Aug 05, 2000
PCT Information
PCT FiledAugust 03, 2001PCT Application Number:PCT/GB01/03495
PCT Publication Date:February 14, 2002PCT Publication Number: WO02/12265

Non-Orange Book US Patents Family Members for Patent 7,101,866

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,144,845 Compounds useful in the manufacture of an anti-inflammatory androstane derivative ➤ Subscribe
7,592,329 Crystalline complexes of fluticasone-2-furoate ➤ Subscribe
7,125,985 Compounds useful in the manufacture of an anti-inflammatory androstane derivative ➤ Subscribe
6,537,983 Anti-inflammatory androstane derivatives ➤ Subscribe
7,541,350 Formulation containing anti-inflammatory androstane derivative ➤ Subscribe
6,858,593 Anti-inflammatory androstane derivative compositions ➤ Subscribe
7,629,335 Anti-inflammatory androstane derivative ➤ Subscribe
6,777,400 Anti-inflammatory androstane derivative compositions ➤ Subscribe
6,878,698 Anti-inflammatory androstane derivatives ➤ Subscribe
7,498,321 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,101,866

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1422 ➤ Subscribe
Argentina 032361 ➤ Subscribe
Argentina 032471 ➤ Subscribe
Argentina 038348 ➤ Subscribe
Argentina 038686 ➤ Subscribe
Argentina 063555 ➤ Subscribe
Austria 342053 ➤ Subscribe
Austria 353908 ➤ Subscribe
Austria 380194 ➤ Subscribe
Austria 396716 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Covington
Harvard Business School
Chinese Patent Office
Queensland Health
Express Scripts
Accenture
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot